Jamie Dananberg Sells 5,521 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) insider Jamie Dananberg sold 5,521 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $2.96, for a total value of $16,342.16. Following the completion of the transaction, the insider now owns 33,479 shares in the company, valued at $99,097.84. The trade was a 14.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Annexon Trading Down 0.7 %

Shares of ANNX stock opened at $2.81 on Friday. The business’s 50-day moving average price is $4.26 and its 200-day moving average price is $5.55. Annexon, Inc. has a 12 month low of $2.63 and a 12 month high of $8.40. The firm has a market capitalization of $299.52 million, a price-to-earnings ratio of -2.68 and a beta of 1.07.

Analysts Set New Price Targets

ANNX has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Annexon in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Annexon currently has a consensus rating of “Buy” and a consensus price target of $15.80.

Institutional Trading of Annexon

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in shares of Annexon by 16.0% during the third quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company’s stock valued at $10,101,000 after purchasing an additional 235,810 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Annexon by 18.3% during the third quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock valued at $12,693,000 after purchasing an additional 331,269 shares in the last quarter. Barclays PLC lifted its stake in shares of Annexon by 212.0% in the third quarter. Barclays PLC now owns 177,765 shares of the company’s stock worth $1,052,000 after acquiring an additional 120,789 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Annexon by 221.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 732,216 shares of the company’s stock worth $4,335,000 after acquiring an additional 504,656 shares during the period. Finally, FMR LLC lifted its stake in shares of Annexon by 3.2% in the third quarter. FMR LLC now owns 8,561,949 shares of the company’s stock worth $50,687,000 after acquiring an additional 262,229 shares during the period.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.